5 outlets·6 reports
OpenAI launches GPT-Rosalind, a specialised AI model for drug discovery and life sciences research
ThinkingNews Desk · how this was written
OpenAI has introduced GPT-Rosalind, a biology-tuned large language model designed for life-sciences research and early-stage drug discovery. The model is being offered as a limited-access research preview, with early customers that include companies such as Moderna and Amgen. It represents OpenAI’s first specialized AI system focused on the biotech sector.
Written from all 5 reports below, not from any single one.
How it was reported
- The Next Web·Amazon launches AI Bio platform to accelerate early-stage drug discovery
- VentureBeat·OpenAI debuts GPT-Rosalind, a new limited access model for life sciences, and broader Codex plugin on Github
- TechMeme·OpenAI launches GPT-Rosalind, an AI model for life sciences research, including drug discovery, as a research preview for customers such as Moderna and Amgen (Megan Morrone/Axios)
- Hacker News·GPT‑Rosalind for life sciences research
- Ars Technica·OpenAI starts offering a biology-tuned LLM
- The Next Web·OpenAI launches GPT-Rosalind, a specialised AI model for drug discovery and life sciences research
Related stories
- OpenAI releases GPT-5.5 and GPT-5.5 Pro in the API6 outlets
- Anthropic and OpenAI announce more powerful (and cheaper) AI models4 outlets
- OpenAI launches GPT-5.4 with native computer use mode, financial plugins for Microsoft Excel, Google Sheets5 outlets
- OpenAI rolls out GPT-5.6 after government green light — and announces ‘ChatGPT Work’6 outlets